References
- Conlan M I. “GAO Report Cites Serious Adverse Drug Reactions in 102 Approved Drugs.”. Drug Topics 1990; 134: 32
- Topol E J, Ellis S G, Califf R M, et al, for the TAMI-4 Study Group. Combined tissue-type plasminogen activator and prostocyclin therapy for acute myocardial infarction. J Am Coll Cardiol 1989; 14: 877–84
- Yusuf S, Sleight P, Held P, McMahon S. Routine medical management of acute mmyocardial infarction. Circulation 1990; 82: II-117–II-134, (suppl II)
- Oliver M F, Heady J A, Morris J N, et al. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate: a report from the committee of principal investigators. Br Heart J 1978; 40: 1069–118
- The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide or flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321: 406–412
- Steering Committee of the Physician's Health Study. Final report on the aspirin component of the ongoing physicians' health study. K Engl J Med 1989; 321: 129–35
- Gore J M, Sloan M, Price T R, et al, the TIMI Investigators. Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the thrombolysis in myocardial infarction study. Circulation 1991; 83: 448–59
- The International Study Group. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomized between alteplase and streptokinase with or without heparin. Lancet 1990; 336: 71–5
- Sleight P, Collins R. The ISIS-3 Trial. Presented at the 40th Annual Scientific Session, American College of Cardiology, Atlanta, March, 51991
- Anderson J L, Karagounis L, Allen A, Bradford M J, Menlove R L, Pryor T A. Older age and elevated blood pressure are risk factors for intracerebral hemorrhage after thrombolysis. Am J Cardiol 1991, (in press)
- Kase C S, O'Neal A M, Fisher M, Gergis G N, Ordia J I. Intracranial hemorrhage after use of tissue plasminogen activator for coronary thrombolysis. Ann Intern Med 1990; 112: 17–121
- ISIS-2 Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. The Lancet 1988; 351–360